Metabolix Inc. (MBLX) Short Interest Down 26.9% in October
Metabolix Inc. (NASDAQ:MBLX) was the target of a significant decline in short interest in October. As of October 31st, there was short interest totalling 413,894 shares, a decline of 26.9% from the October 14th total of 566,253 shares. Based on an average daily volume of 37,378 shares, the short-interest ratio is presently 11.1 days. Approximately 3.8% of the shares of the company are sold short.
In related news, major shareholder William P. Scully sold 165,000 shares of the business’s stock in a transaction dated Friday, September 9th. The stock was sold at an average price of $0.35, for a total value of $57,750.00. Following the transaction, the insider now owns 3,066,666 shares in the company, valued at approximately $1,073,333.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 13.70% of the company’s stock.
An institutional investor recently bought a new position in Metabolix stock. GMT Capital Corp purchased a new stake in shares of Metabolix Inc. (NASDAQ:MBLX) during the second quarter, according to its most recent disclosure with the SEC. The firm purchased 335,617 shares of the company’s stock, valued at approximately $279,000. GMT Capital Corp owned approximately 1.21% of Metabolix at the end of the most recent quarter. 13.53% of the stock is currently owned by hedge funds and other institutional investors.
Metabolix (NASDAQ:MBLX) opened at 0.33 on Friday. Metabolix has a 12 month low of $0.26 and a 12 month high of $2.29. The firm’s market cap is $9.28 million. The company has a 50-day moving average price of $0.47 and a 200 day moving average price of $0.64.
Metabolix (NASDAQ:MBLX) last announced its quarterly earnings results on Wednesday, November 9th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.09. Metabolix had a negative return on equity of 210.86% and a negative net margin of 261.19%. Equities research analysts anticipate that Metabolix will post ($0.22) EPS for the current year.
Metabolix Company Profile
Metabolix, Inc is an advanced biomaterials company. The Company operates through the business of developing and commercializing technologies for the production of polymers and chemicals in microbes and plants segment. The Company is focused on delivering solutions to the plastics industry. The Company has its operations in the microbial genetics, fermentation process engineering, chemical engineering, polymer science, plant genetics and botanical science.
Receive News & Stock Ratings for Metabolix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metabolix Inc. and related stocks with our FREE daily email newsletter.